Daniel Canterbury resumes & CV records
Resumes
Daniel P Canterbury, 4559 Somersett Dr, Pawcatuck, CT 06379
Daniel Canterbury Phones & Addresses
59 Somersett Dr, Pawcatuck, CT 06379
Mystic, CT
Groton, CT
919 87Th St, Niagara Falls, NY 14304 716-2839714
2014 Townhall Ter #5, Grand Island, NY 14072 716-6937543
Rochester, NY
North Tonawanda, NY
Palm Bch Gdns, FL
Social networks
Daniel P Canterbury
Linkedin
Mentions for Daniel P Canterbury
Publications & IP owners
Us Patents
(Aza)Benzothiazolyl Substituted Pyrazole Compounds
US Patent:
2022018, Jun 16, 2022
Filed:
Nov 23, 2021
Appl. No.:
17/533592
Inventors:
- New York NY, US
Daniel Paul Canterbury - Pawcatuck CT, US
Robert Lee Dow - Groton CT, US
Andrew Fensome - Harvard MA, US
Magdalena Korczynska - Somerville MA, US
Sophie Yvette Lavergne - Waterford CT, US
Allyn Timothy Londregan - Barrington RI, US
Vincent Mascitti - Westwood MA, US
David Walter Piotrowski - Waterford CT, US
Andre Shavnya - East Lyme CT, US
Meihua Mike Tu - Acton MA, US
Tao Wang - Sudbury MA, US
Hanna Maria Wisniewska - San Diego CA, US
Daniel Paul Canterbury - Pawcatuck CT, US
Robert Lee Dow - Groton CT, US
Andrew Fensome - Harvard MA, US
Magdalena Korczynska - Somerville MA, US
Sophie Yvette Lavergne - Waterford CT, US
Allyn Timothy Londregan - Barrington RI, US
Vincent Mascitti - Westwood MA, US
David Walter Piotrowski - Waterford CT, US
Andre Shavnya - East Lyme CT, US
Meihua Mike Tu - Acton MA, US
Tao Wang - Sudbury MA, US
Hanna Maria Wisniewska - San Diego CA, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A61K 31/428
C07D 417/04
C07D 513/04
A61K 31/437
A61K 31/353
A61K 31/423
A61K 31/415
A61K 31/192
A61K 31/12
A61K 31/7105
C07D 417/04
C07D 513/04
A61K 31/437
A61K 31/353
A61K 31/423
A61K 31/415
A61K 31/192
A61K 31/12
A61K 31/7105
Abstract:
This application includes a compound of Formula Ior a pharmaceutically acceptable salt thereof; wherein the variables R, R, R, R, X, Y and Z are as defined herein, pharmaceutical compositions comprising the compounds of Formula I and methods of treatment comprising administering to a patient in need thereof a compound of Formula I for the treatment of transthyretin amyloidosis and diseases related thereto.
Antagonists Of Prostaglandin Ep3 Receptor
US Patent:
2016017, Jun 23, 2016
Filed:
Dec 16, 2015
Appl. No.:
14/970930
Inventors:
- New York NY, US
Daniel Canterbury - Groton CT, US
David James Edmonds - Arlington MA, US
Kentaro Futatsugi - Quincy MA, US
Esther Cheng Yin Lee - Brookline MA, US
Elnaz Menhaji-Klotz - Somerville MA, US
Jana Polivkova - Mystic CT, US
Robert Vernon Stanton - Belmont MA, US
Daniel Canterbury - Groton CT, US
David James Edmonds - Arlington MA, US
Kentaro Futatsugi - Quincy MA, US
Esther Cheng Yin Lee - Brookline MA, US
Elnaz Menhaji-Klotz - Somerville MA, US
Jana Polivkova - Mystic CT, US
Robert Vernon Stanton - Belmont MA, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
C07D 401/14
Abstract:
Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.